Streetbeat News

Stock Prices

WOOF

Over the past 3 months, 7 analysts have published their opinion on Petco Health and Wellness (NASDAQ:WOOF) stock. The analysts have an average price target of $7.43 versus the current price of $5.205, implying an upside. This current average represents a 28.76% decrease from the previous average price target of $10.43.

Portfolio Pulse from Benzinga Insights

August 25, 2023 | 6:00 pm

KLAC

KLA (NASDAQ:KLAC) has outperformed the market over the past 20 years, producing an average annual return of 11.06%. If an investor had bought $100 of KLAC stock 20 years ago, it would be worth $814.63 today. The company currently has a market capitalization of $65.00 billion.

Portfolio Pulse from Benzinga Insights

August 25, 2023 | 6:00 pm

MSI

Motorola Solutions (NYSE:MSI) has outperformed the market over the past 10 years, producing an average annual return of 17.34%. If an investor had bought $1000 of MSI stock 10 years ago, it would be worth $4,930.93 today. The company currently has a market capitalization of $46.44 billion.

Portfolio Pulse from Benzinga Insights

August 25, 2023 | 6:00 pm

TD

In the last quarter, Toronto-Dominion Bank (NYSE:TD) received 2 somewhat bullish and 2 indifferent analyst ratings. The average 12-month price target for the company is $88.0, a decrease of 0.56% from the previous average of $88.50.

Portfolio Pulse from Benzinga Insights

August 25, 2023 | 6:00 pm

SIG

Telsey Advisory Group analyst Dana Telsey has reiterated a Market Perform rating on Signet Jewelers Ltd (SIG) with a price target of $71. The analyst expects SIG's Q2 results to show an EPS of $1.37 and total sales to decrease by 11.1% Y/Y to $1.56 billion. The company's operating expense and capital expenditures are expected to weigh on operating margin, resulting in a range of 8.9% - 9.2%. The analyst also noted that SIG's significant exposure to the bridal segment is not expected to recover until late 2024.

Portfolio Pulse from Shivani Kumaresan

August 25, 2023 | 5:59 pm

RYZB

Radiopharmaceuticals startup RayzeBio Inc has filed for an initial public offering (IPO) to raise up to $100 million. The company, which focuses on cancer therapies, plans to list on the Nasdaq under the symbol RYZB. Its lead candidate, RYZ101, is designed to deliver a potent alpha particle radioisotope to tumors. The IPO proceeds will also be used to develop RYZ801 and RYZ811, two radiopharmaceuticals for phase 1 trials in hepatocellular carcinoma. RayzeBio has already secured $418 million in funding from investors including venBio Partners, Venrock Healthcare Capital Partners, Versant Ventures, and Viking Global Investors.

Portfolio Pulse from Vandana Singh

August 25, 2023 | 5:56 pm

ENDPQ

MNK

RAD

Rite Aid Corp (NYSE:RAD) is reportedly on the brink of bankruptcy due to its role in the opioid crisis and a significant debt burden exceeding $3.3 billion. The company is facing numerous lawsuits and has seen its stock value drop by over 80% within a year. Other pharmaceutical companies like Purdue Pharma, Mallinckrodt Plc (NYSE:MNK), and Endo International Plc (OTC:ENDPQ) have also faced bankruptcy due to opioid-related litigations.

Portfolio Pulse from Vandana Singh

August 25, 2023 | 5:52 pm

AZN

BMY

JNJ

LLY

MRK

PFE

AstraZeneca has announced a legal challenge against the U.S. government's Inflation Reduction Act (IRA) that allows Medicare to negotiate more competitive drug prices. Other pharmaceutical companies including Johnson & Johnson, Merck & Co, Bristol Myers Squibb, Eli Lilly, and Pfizer have echoed this sentiment, suggesting that such a provision threatens the innovation and development of new therapeutic solutions. The pharmaceutical world is watching closely as the U.S. Department of Health and Human Services is set to negotiate prices for ten high-value drugs next month.

Portfolio Pulse from Vandana Singh

August 25, 2023 | 5:49 pm

XOM

A significant investor has taken a bearish stance on Exxon Mobil (NYSE:XOM), with 55% of recent trades being bearish and 45% bullish. The total amount for puts is $703,616 and for calls is $1,514,683. Whales have been targeting a price range from $55.0 to $116.0 for Exxon Mobil over the last 3 months. The current price of XOM is up 1.49% at $107.93. Mizuho, UBS, and Morgan Stanley have maintained their Buy and Overweight ratings on Exxon Mobil, with price targets of $131, $139, and $124 respectively.

Portfolio Pulse from Benzinga Insights

August 25, 2023 | 5:46 pm

GS

A significant bearish stance has been taken on Goldman Sachs Gr (NYSE:GS) as indicated by unusual options activity. The sentiment among these big-money traders is 80% bearish and 20% bullish. The whales have been targeting a price range from $270.0 to $380.0 for Goldman Sachs Gr over the last 3 months. The price of GS is currently down -0.31% at $318.98. Atlantic Equities upgraded its action to Neutral with a price target of $351, while Oppenheimer maintained their Outperform rating with a price target of $461.

Portfolio Pulse from Benzinga Insights

August 25, 2023 | 5:46 pm